Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step

Andreas Otte*, Christophe van de Wiele, Rudi A. Dierckx

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    11 Citations (Scopus)

    Abstract

    Radiolabeled immunotherapy (RIT) is becoming a significant step forward in the treatment management of non-Hodgkin's lymphoma (NHL). In this state-of-the-art review article, general details, practical and health economic aspects, and next steps of RIT in NHL are reviewed from the existing literature and latest abstracts. As Y-90-ibritumomab tiuxetan is the only marketed RIT in NHL in Europe, the special focus of this review is on 90Y-ibritumomab tiuxetan, although the whole spectrum of available RIT concepts is highlighted. There is strong evidence to suggest that RIT is not only a safe and efficacious add-on treatment option in third or second line to chemotherapy, but is also a convincing asset as first-line therapy in various indications of lymphoma. Nucl Med Commun 30:5-15 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

    Original languageEnglish
    Pages (from-to)5-15
    Number of pages11
    JournalNuclear Medicine Communications
    Volume30
    Issue number1
    DOIs
    Publication statusPublished - Jan-2009

    Keywords

    • chemotherapy
    • I-131-labeled tositumomab (Bexxar)
    • non-Hodgkin's lymphoma
    • radiolabeled immunotherapy
    • Y-90-ibritumomab tiuxetan (Zevalin)
    • IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY
    • B-CELL LYMPHOMA
    • ALPHA-EMITTING RADIOIMMUNOCONJUGATE
    • RADIATION SAFETY CONSIDERATIONS
    • ANTI-CD22 MONOCLONAL-ANTIBODY
    • RANDOMIZED CONTROLLED TRIAL
    • NERVOUS-SYSTEM LYMPHOMA
    • MALIGNANT-LYMPHOMA
    • LOW-GRADE
    • MULTICENTER TRIAL

    Cite this